CD38 and lymphoma: Several groups have published studies targeting T cell malignancies with CAR NK‐92 cells, an Interleukin (IL2)‐dependent NK‐lymphoma‐derived cell line.[30, 31, 32] For target antigens that are also expressed in primary NK cells, one study applied CRISPR/Cas9 gene editing to disrupt the CD38 gene of NK cells to reduce fratricide and then transduced CD38 CAR into NK cells and tested their efficacy against AML.[28]